Rekah Pharmaceutical Operating Margin vs. Revenue

REKA Stock  ILA 1,400  8.00  0.57%   
Taking into consideration Rekah Pharmaceutical's profitability measurements, Rekah Pharmaceutical Industry may not be well positioned to generate adequate gross income at the moment. It has a very high risk of underperforming in January. Profitability indicators assess Rekah Pharmaceutical's ability to earn profits and add value for shareholders.
For Rekah Pharmaceutical profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Rekah Pharmaceutical to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Rekah Pharmaceutical Industry utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Rekah Pharmaceutical's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Rekah Pharmaceutical Industry over time as well as its relative position and ranking within its peers.
  
Check out Your Equity Center.
Please note, there is a significant difference between Rekah Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Rekah Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Rekah Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Rekah Pharmaceutical Revenue vs. Operating Margin Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Rekah Pharmaceutical's current stock value. Our valuation model uses many indicators to compare Rekah Pharmaceutical value to that of its competitors to determine the firm's financial worth.
Rekah Pharmaceutical Industry is currently regarded as top stock in operating margin category among its peers. It also is currently regarded number one company in revenue category among its peers totaling about  5,135,214,008  of Revenue per Operating Margin. Comparative valuation analysis is a catch-all model that can be used if you cannot value Rekah Pharmaceutical by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Rekah Pharmaceutical's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

Rekah Revenue vs. Operating Margin

Operating Margin shows how much operating income a company makes on each dollar of sales. It is one of the profitability indicators which helps analysts to understand whether the firm is successful or not making money from everyday operations.

Rekah Pharmaceutical

Operating Margin

 = 

Operating Income

Revenue

X

100

 = 
0.05 %
A good Operating Margin is required for a company to be able to pay for its fixed costs or payout its debt, which implies that the higher the margin, the better. This ratio is most effective in evaluating the earning potential of a company over time when comparing it against a firm's competitors.
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.

Rekah Pharmaceutical

Revenue

 = 

Money Received

-

Discounts and Returns

 = 
263.95 M
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include products or services discounts, promotions, as well as early payments on invoices or services rendered in advance.

Rekah Revenue vs Competition

Rekah Pharmaceutical Industry is currently regarded number one company in revenue category among its peers. Market size based on revenue of Health Care industry is at this time estimated at about 28.8 Billion. Rekah Pharmaceutical maintains roughly 263.95 Million in revenue contributing less than 1% to equities under Health Care industry.

Rekah Pharmaceutical Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Rekah Pharmaceutical, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Rekah Pharmaceutical will eventually generate negative long term returns. The profitability progress is the general direction of Rekah Pharmaceutical's change in net profit over the period of time. It can combine multiple indicators of Rekah Pharmaceutical, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Rekah Pharmaceutical Industry Ltd. engages in the manufacture, marketing, sale, and distribution of prescription and OTC drugs, dermo-cosmetics, vitamins, and nutritional supplements in Israel. The company was founded in 1941 and is based in Holon, Israel. REKAH PHARMA operates under Drug ManufacturersSpecialty Generic classification in Israel and is traded on Tel Aviv Stock Exchange. It employs 9 people.

Rekah Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Rekah Pharmaceutical. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Rekah Pharmaceutical position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Rekah Pharmaceutical's important profitability drivers and their relationship over time.

Use Rekah Pharmaceutical in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Rekah Pharmaceutical position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Rekah Pharmaceutical will appreciate offsetting losses from the drop in the long position's value.

Rekah Pharmaceutical Pair Trading

Rekah Pharmaceutical Industry Pair Trading Analysis

The ability to find closely correlated positions to Rekah Pharmaceutical could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Rekah Pharmaceutical when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Rekah Pharmaceutical - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Rekah Pharmaceutical Industry to buy it.
The correlation of Rekah Pharmaceutical is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Rekah Pharmaceutical moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Rekah Pharmaceutical moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Rekah Pharmaceutical can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Rekah Pharmaceutical position

In addition to having Rekah Pharmaceutical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Natural Foods Thematic Idea Now

Natural Foods
Natural Foods Theme
Companies producing natural foods including dairy products and different types of meets. The Natural Foods theme has 37 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Natural Foods Theme or any other thematic opportunities.
View All  Next Launch

Other Information on Investing in Rekah Stock

To fully project Rekah Pharmaceutical's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Rekah Pharmaceutical at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Rekah Pharmaceutical's income statement, its balance sheet, and the statement of cash flows.
Potential Rekah Pharmaceutical investors and stakeholders can use historical trends found within financial statements to determine how well the company is positioned for the future. Although Rekah Pharmaceutical investors may work on each financial statement separately, they are all related. The changes in Rekah Pharmaceutical's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Rekah Pharmaceutical's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet but not equivalent to net income shown on the income statement. Please read more on our technical analysis and fundamental analysis pages.